TOP HEADLINES

Editor's Corner

Cleveland Clinic crew identifies possible lung cancer biomarkers

Cleveland Clinic scientists believe they have identified possible blood biomarkers that could help detect lung cancer, based on the alteration of metabolic processes that happens to patients with the disease at various stages.

Xagenic names CEO to help commercialize lab-free molecular Dx tech

Xagenic, a startup focused on developing a quick, automated, lab-free molecular diagnostic system, has dipped into the life sciences entrepreneurial world to hire its president and CEO.

Celgene takes equity stake in Sequenta and its precise Dx tech

Sequenta attracted new equity investment from Celgene and other unnamed parties that back the use of its technology in the drug development process and the creation of new ultraprecise diagnostic tests.

BioMérieux subsidiary nails Medicare coverage for breast cancer molecular test

A subsidiary of French in vitro diagnostics giant bioMérieux gained Medicare coverage for a new breast cancer test, a vital milestone necessary to compete in today's market.

Virginia Tech finds possible biomarker for rare immunodeficiency condition

Virginia Tech researchers believe they've found a possible biomarker to help detect a rare genetic disease known as severe combined immunodeficiency, or SCID, which leaves patients needing to avoid all human contact and breathe filtered air in order to survive.

MORE NEWS

From Our Sister Sites

FierceVaccines

To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.

FierceVaccines

GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.